Country
Netherlands
Galapagos NV ended 2020 with a strong balance sheet but a reconfigured pipeline following its decision, together with partner Gilead Sciences Inc, to abandon plans to pursue a US marketing authorisation for Jyseleca (filgotinib), it
Full text available to subscribers only. Click here for information on subscribing to MedNous.